Search
Magnesium cation
go.drugbank.com/drugs/DB01378ApprovedInvestigationalNutraceuticalWithdrawnMagnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. … draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in
Synonyms: Magnesium ion, Magnesium, ion(Mg2+)Mixtures: KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 30 ADET, KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 40 ADETRilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationaland Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. … Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS)
Categories: Receptors, Interleukin-1 Type ISynonyms: IL-1 TRAP, IL-1-TRAPAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalApproved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC
Lonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigationalHutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment
Selegiline
go.drugbank.com/drugs/DB01037ApprovedInvestigationalVet approvedIt is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. … It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
Categories: Compounds used in a research, industrial, or household settingCetyl alcohol
go.drugbank.com/drugs/DB09494ApprovedCetyl alcohol is present in a waxy white powder or flake form at room temperature, and is insoluble in water and soluble in alcohols and oils [A32209]. … Discovered by Chevrenl in 1913, cetyl alcohol is one of the oldest known long-chain alcohol [A32209]. It may be contained in cosmetic and personal care products such as shampoos, creams and lotions.
Echinacoside
go.drugbank.com/drugs/DB15488Investigational[A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,
Dalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.